Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01223027 · ClinicalTrials.gov registry record · Phase 3
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 564
- Enrollment target
NCT01223027 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 564 participants.
The verdict
NCT01223027, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 564 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
Interventions
- DRUG Sorafenib
- DRUG Dovitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01223027
The ClinicalTrials.gov registry entry for NCT01223027 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01223027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01223027 about?
NCT01223027 is a clinical study titled "Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma". This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
What is the current status of trial NCT01223027?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 564 participants. The study started on 2011-03. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01223027?
The interventions under investigation include: Sorafenib (DRUG), Dovitinib (DRUG).
Who is sponsoring clinical trial NCT01223027?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.